Back to Search Start Over

Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia

Authors :
Clot, Fabienne
Grabli, David
Cazeneuve, Cécile
Roze, Emmanuel
Castelnau, Pierre
Chabrol, Brigitte
Landrieu, Pierre
Nguyen, Karine
Ponsot, Gérard
Abada, Myriem
Doummar, Diane
Damier, Philippe
Gil, Roger
Thobois, Stéphane
Ward, Alana J.
Hutchinson, Michael
Toutain, Annick
Picard, Fabienne
Camuzat, Agnès
Fedirko, Estelle
Sân, Chankannira
Bouteiller, Delphine
LeGuern, Eric
Durr, Alexandra
Vidailhet, Marie
Brice, Alexis
Clot, Fabienne
Grabli, David
Cazeneuve, Cécile
Roze, Emmanuel
Castelnau, Pierre
Chabrol, Brigitte
Landrieu, Pierre
Nguyen, Karine
Ponsot, Gérard
Abada, Myriem
Doummar, Diane
Damier, Philippe
Gil, Roger
Thobois, Stéphane
Ward, Alana J.
Hutchinson, Michael
Toutain, Annick
Picard, Fabienne
Camuzat, Agnès
Fedirko, Estelle
Sân, Chankannira
Bouteiller, Delphine
LeGuern, Eric
Durr, Alexandra
Vidailhet, Marie
Brice, Alexis

Abstract

Dopa-responsive dystonia is a childhood-onset dystonic disorder, characterized by a dramatic response to low dose of l-Dopa. Dopa-responsive dystonia is mostly caused by autosomal dominant mutations in the GCH1 gene (GTP cyclohydrolase1) and more rarely by autosomal recessive mutations in the TH (tyrosine hydroxylase) or SPR (sepiapterin reductase) genes. In addition, mutations in the PARK2 gene (parkin) which causes autosomal recessive juvenile parkinsonism may present as Dopa-responsive dystonia. In order to evaluate the relative frequency of the mutations in these genes, but also in the genes involved in the biosynthesis and recycling of BH4, and to evaluate the associated clinical spectrum, we have studied a large series of index patients (n = 64) with Dopa-responsive dystonia, in whom dystonia improved by at least 50% after l-Dopa treatment. Fifty seven of these patients were classified as pure Dopa-responsive dystonia and seven as Dopa-responsive dystonia-plus syndromes. All patients were screened for point mutations and large rearrangements in the GCH1 gene, followed by sequencing of the TH and SPR genes, then PTS (pyruvoyl tetrahydropterin synthase), PCBD (pterin-4a-carbinolamine dehydratase), QDPR (dihydropteridin reductase) and PARK2 (parkin) genes. We identified 34 different heterozygous point mutations in 40 patients, and six different large deletions in seven patients in the GCH1 gene. Except for one patient with mental retardation and a large deletion of 2.3 Mb encompassing 10 genes, all patients had stereotyped clinical features, characterized by pure Dopa-responsive dystonia with onset in the lower limbs and an excellent response to low doses of l-Dopa. Dystonia started in the first decade of life in 40 patients (85%) and before the age of 1 year in one patient (2.2%). Three of the 17 negative GCH1 patients had mutations in the TH gene, two in the SPR gene and one in the PARK2 gene. No mutations in the three genes involved in the biosynthesis and rec

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn999836117
Document Type :
Electronic Resource